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Summary
Head and neck squamous cell carcinoma (HNSCC) is a
frequent tumour arising from multiple anatomical subsites
in the head and neck region. The treatment for early-
stage disease is generally single modality, either surgery
or radiotherapy. The treatment for locally advanced tu-
mours is multimodal. For recurrent/metastatic HNSCC pal-
liative chemotherapy is standard of care. The prognosis
is limited and novel treatment approaches are urgently
needed. HNSCC evades immune responses through mul-
tiple resistance mechanisms. HNSCC is particularly char-
acterised by an immunosuppressive environment which
includes the release of immunosuppressive factors, acti-
vation, expansion of immune cells with inhibitory activity
and decreased tumour immunogenicity. An in-depth un-
derstanding of these mechanisms led to rational design
of immunotherapeutic approaches and clinical trials. Cur-
rently, only immune checkpoint inhibitors, namely mono-
clonal antibodies targeting the immune inhibitory recep-
tor programmed cell death 1 (PD-1) and its ligand PD-L1
have proven clinical efficacy in randomised phase III trials.
The PD-1 inhibitor nivolumab is the only drug approved
for platinum-refractory recurrent/metastatic HNSCC. How-
ever, many more immunotherapeutic treatment options
are currently under investigation. Ongoing trials are in-
vestigating immunotherapeutic approaches also in the cu-
rative setting and combination therapies using different
immunotherapeutic approaches. This review article sum-
marises current knowledge of the role of the immune sys-
tem in the development and progression of HNSCC, and
provides a comprehensive overview on the development
of immunotherapeutic approaches.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is one
of the most common malignancies worldwide, accounting
for more than 550,000 new cases and 380,000 deaths per
year [1, 2]. These tumours arise from different anatomic
subsites in the head and neck region, and include nasopha-
ryngeal carcinoma, oral cavity carcinoma, oropharyngeal
carcinoma, laryngeal carcinoma and hypopharyngeal car-
cinoma. Beside the well-established risk factors such as
tobacco smoking and alcohol consumption, human papil-
loma virus (HPV) infection has recently become an impor-
tant factor in the epidemiology and prognosis of HNSCC,
mainly in the oropharyngeal region [3, 4]. Most patients
are diagnosed when they have locally advanced disease
and are usually treated with multimodal therapy including
surgery, radiotherapy and systemic therapy. Therefore, an
up-front interdisciplinary approach is a basic principle for
these patients. Despite advances in surgical and radiation
techniques, as well as the addition of chemotherapy and
epidermal growth factor receptor (EGFR)-targeting mono-
clonal antibodies in the treatment of locally advanced HN-
SCC, more than half of patients eventually experience a
relapse or distant metastases. Most of these patients are
no longer suitable for curative treatment approaches. For
locally recurrent disease, local treatment options such as
surgery and radiotherapy play an important role. For re-
current disease no longer amenable to local therapy or
metastatic HNSCC, cytotoxic chemotherapy remains the
standard treatment option. Even with modern multi-agent
chemotherapy, the expected median survival for a patient
with an incurable or metastatic relapse remains under a
year, or marginally longer for patients who develop metas-
tases from an HPV-related HNSCC [5, 6]. The addition of
an EGFR-targeting monoclonal antibody has been shown
to improve overall survival compared with platinum-based
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chemotherapy alone by 2.7 months [7]. Although early
clinical immunotherapy trials have yielded mixed results
with ambiguous clinical benefit [8], cancer immunother-
apy is nowadays regarded as an important pillar of anti-
cancer treatment. The increasing knowledge as to how the
immune system works, in particular with regard to chronic
viral infections and cancer, has paved the way for the ratio-
nal development of novel treatment strategies [9].
This review focuses on the currently approved im-
munotherapy, as well as promising immunotherapeutic ap-
proaches under clinical investigation.
Head and neck cancer and the immune system
In recent years, a key role for the immune system in control
of tumour growth and progression has been well estab-
lished [10, 11]. The lymphocytic infiltrate of tumours is
known to be associated with the prognosis of malignant tu-
mours [12–14]. In HNSCC, a high density of tumour-in-
filtrating lymphocytes (TILs) is associated with improved
outcome of patients [15, 16]. A correlation with outcome
has mainly been shown for CD8+ lymphocytes [17]. The
rate of CD8+ infiltrating effector lymphocytes is higher in
HPV-positive cancers, which might at least partially ex-
plain their better clinical outcome [17, 18]. Regulatory T
cells (Tregs) control autoreactive lymphocytes, but also
downregulate the immune response to tumour-associated
antigens. Tregs have been regularly described among TILs
and in the peripheral circulation in various solid tumours
[19–22]. Our own findings support previous findings of in-
creased rate of Tregs in the microenvironment of HNSCC
[23–26]. Furthermore, we found an increased rate of Tregs
in the peripheral circulation of HNSCC patients compared
with healthy controls, suggesting a systemic immunosup-
pressive environment in HNSCC patients [23]. Dendritic
cells play an important role in the initiation of tumour anti-
gen-specific T cell responses and subgroups of dendritic
cells have the unique ability to present captured exoge-
nous tumour antigens on major hisotocompatibility com-
plex class I molecules (“cross-presentation”). Therefore,
both naïve CD4+ and naïve CD8+ T cells are activated and
differentiated into tumour-antigen-specific effector T cells
by mature dendritic cells in lymph nodes [27]. High den-
dritic cell infiltration in the tumour is significantly corre-
lated with improved outcome in HNSCC patients [28].
Immunological responses in tumours are carefully regulat-
ed through expression of both stimulatory and inhibitory
signals. Cytotoxic T lymphocyte-associated antigen 4 (CT-
LA-4) and programmed death 1 (PD-1) are two membrane
proteins expressed by T cells involved in maturation and
suppressive functions of TILs [29, 30]. These immune
checkpoint receptors are characteristic of exhausted T cells
found after long-term antigen exposure [31, 32]. Exhausted
T cells are incapable of robust effector responses upon
antigen exposure [33, 34]. PD-1 and CTLA-4 are highly
expressed in regulatory Tregs of HNSCC tissue compared
with peripheral blood, suggesting a suppressive function
of Tregs in the tumour tissue [35, 36]. On the other hand,
PD-1+ cells were found to be increased and associated
with an improved prognosis in the setting of HPV-positive
tumours [18, 26, 37]. The PD-1 receptor has two ligands,
PD-L1 and PD-L2 [38]. Both receptors are up-regulated
under inflammatory conditions, mediated, in part, by type
I and type II interferons. Furthermore, PD-L1 and, to a
lesser extent, PD-L2 are expressed on many human solid
and haematological tumours [39]. Several recent studies
demonstrated that PD-L1 expression is closely correlated
to tumour grade and prognosis in patients with various
solid malignancies [40–42]. In HNSCC, high PD-L1 ex-
pression was associated with metastasis and poor outcome
[43]. In a recently published study we provided the first
comprehensive analysis of multiple T cell subsets and the
expression of clinically relevant immune checkpoint recep-
tors in treatment-naïve HNSCC in comparison with non-
cancerous oral mucosa and peripheral blood of patients and
healthy donors [23]. Briefly, our study showed a decrease
in naïve T cells and an increase in Tregs in the tumour
microenvironment. Inhibitory immune checkpoint recep-
tors (CTLA-4, PD-1 and PD-L1) were increased in TILs.
PD-L1 expression in HNSCC was described in 66 to 87%
of HNSCC primary tumours [35]. Another recent study
showed increased expression of the co-stimulatory check-
point receptor, OX40 [36]. Additional immune check-
points (e.g., TIM-3 [T cell immunoglobulin mucin receptor
3], LAG3 [lymphocyte-activation gene 3], TIGIT [T cell
immunoreceptor with Ig and ITIM domains]) have been
described and their targeting is being tested in early phase
clinical trials.
Differences in the immune infiltrate of HPV-positive and
HPV-negative tumours have been described. HPV-positive
tumours are characterised by an adaptive host immune re-
sponse directed against viral antigens, as well as specific T
cells directed against viral proteins [44–46]. Moreover, the
tumour microenvironment of HPV-positive tumours has
been shown to contain a higher number of CD8+ T cells
and a decreased CD4/CD8 ratio [18, 46]. We and others
described higher PD-1 expression in TILs of HPV-positive
tumours, probably reflecting a strong immune response in-
duced by HPV [18, 23]. However, another study showed
high PD-1 levels in HPV-negative HNSCC [47]. In our
study we found a trend towards a higher number of tu-
mour-infiltrating Tregs in HPV-negative tumours, poten-
tially corresponding to a more immunosuppressive tumour
microenvironment in HPV-negative tumours [23]. With re-
gard to expression of PD-L1 there are conflicting data con-
cerning its correlation to HPV status [48–50]
Vaccines
The basic principles of therapeutic cancer vaccines are,
briefly:
1. Peptide/protein-based vaccines are produced by com-
bining one or more peptides or proteins commonly ex-
pressed in the specific tumour with an adjuvant. In
response to the adjuvant the immune system will al-
so respond to tumour cells that express the respective
antigens.
2. DNA/RNA-based vaccines use exogenously manipu-
lated nucleic acids expressing a tumour-specific anti-
gen when injected. This antigen is processed by anti-
gen-presenting cells, inducing a specific immune re-
sponse toward tumour cells expressing the same anti-
gen.
3. Attenuated bacteria and viral vectors can serve as vec-
tors to deliver proteins of interest or plasmids encoding
genes in vaccines [51, 52].
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4. For dendritic cell vaccines, dendritic cells are isolated
from the blood of cancer patients by leucapheresis and
stimulated with a tumour antigen. The cells are rein-
jected and are supposed to activate tumour-specific T
cells.
Though the potential of vaccines for therapeutic efficacy
has been extensively demonstrated in tumour models, clin-
ical trials with vaccines have failed in melanoma and non-
small-cell lung cancer [9]. Therefore, vaccination ap-
proaches are currently tested in combination with other
immunotherapeutic approaches.
Peptide/protein-based vaccines
Although the incidence of alcohol- and smoking-induced
HNSCC is steadily declining, the incidence of HPV-associ-
ated oropharyngeal carcinoma has rapidly increased during
the last decades in developed countries worldwide [53].
Approximately 90% of these cases are caused by HPV16
and the remainder by other oncogenic HPV types [53, 54].
It is estimated that the number of HPV-positive HNSCCs
will surpass the annual number of cervical cancers diag-
nosed within the US by the year 2020 [53]. Randomised
trials of prophylactic HPV vaccines have demonstrated ef-
fective prevention of high-grade cervical lesions associat-
ed with HPV16 and HPV18 [55]. Therefore, prophylactic
HPV vaccination with the bivalent (HPV16/18) or quadri-
valent (HPV16/18/6/11) vaccine is currently recommend-
ed for young females to prevent genital warts, and cervical,
anal, vulvar and vaginal precancerous lesions worldwide,
including in Switzerland [56]. Further randomised trials al-
so showed significantly reduced HPV-associated anogeni-
tal lesions in male [57]. This led to the approval of prophy-
lactic vaccination also for boys and young males [56]. Very
recently, a cross-sectional study showed that HPV vacci-
nation significantly reduced the prevalence of oral HPV16/
18/6/11 infections (0.11 vs 1.61%, p = 0.008) [58]. This
corresponds to an estimated 88.2% reduction in prevalence
after model adjustment for age, gender and race. The effect
was more pronounced in males (prevalence 0.0 vs 2.13%,
p = 0.007). Despite the effectiveness of prophylactic HPV
vaccination, widespread general adoption and administra-
tion of HPV vaccination is poor [59].
The cyclin-dependent kinase inhibitor p16(INK4a) is
strongly and consistently overexpressed in HPV-associated
cancers. A recently published study investigated a
p16(INK4a)-based peptide vaccine in patients with ad-
vanced HPV-positive HNSCC [60]. A total of 20 patients
received at least four injections and were evaluated for im-
mune responses. CD4+ T cells were detected in 14 of 20
patients, CD8+ T cells were detected in 5 of 20 patients,
and antibodies were detected in 14 of 20 patients. Vacci-
nation was safe with low toxicity rates. Tumour response
could be assessed in 14 patients. Of these, nine patients
(64%) had stable disease as their best overall response. In
the VICORYX-2 trial this vaccination is being investigated
in combination with cisplatin-based chemotherapy in pa-
tients with advanced HPV-positive cervical, vulvar, vagi-
nal, penile, anal or head and neck cancer (NCT02526316).
A study with an immunomodulatory peptide vaccine for
HPV-positive and melanoma antigen A3-positive tumours
elicited antigen-specific T cells and antibody responses to
the respective vaccines, but lacked clinical efficacy [61].
In another phase I/II study, the safety profile of AlloVax,
a vaccine composed of a patient-specific tumour antigen
derived from chaperone-rich tumour cell lysate is being
investigated in patients with recurrent/metastatic HNSCC
(NCT01998542). Recently, personalised neoantigen vac-
cines have been developed and investigated [62]. This ap-
proach is based on massively parallel sequencing for de-
tection of all coding mutations within tumours, and of
machine learning approaches to reliably predict which mu-
tated peptides have high-affinity binding of autologous hu-
man leukocyte antigen (HLA) molecules.
DNA/RNA-based vaccines
Several attempts to use therapeutic HPV vaccines have
been made. MEDI0457 (previously called INO-3112) is
a DNA-based cancer vaccine with two main components:
VGX-3100, a DNA plasmid containing modified se-
quences for E6 and E7, and INO-9012, a DNA plasmid
containing the immune activator interleukin-12. Prelimi-
nary results from a phase I/II trial demonstrated that this
DNA-based immunotherapy can safely generate HPV-spe-
cific CD8 T cell immunity in patients with locally ad-
vanced HPV-related HNSSC [63]. All tested patients had
positive cellular immune responses in at least one assay. In
an ongoing phase I/II study MEDI0457 is being investigat-
ed in combination with the anti-PD-L1 antibody durvalum-
ab in patients with HPV-positive recurrent/metastatic HN-
SCC (NCT03162224).
Recently, a phase II trial with a multipeptide vaccine for
three cancer-testis-antigens (LY6K, CDCA1 and IMP3)
showed a significant survival benefit (median overall sur-
vival 4.9 vs 3.5 months, p <0.05) compared with an un-
treated cohort in recurrent/metastatic HNSCC [64].
Attenuated bacteria and viral vectors
ADXS11-001 is a live attenuated Listeria monocytogenes
(Lm)-listeriolysin O (LLO) immunotherapy bioengineered
to secrete an HPV-E7 tumour antigen as a truncated LLO-
E7 fusion protein in cells capable of presenting antigen. An
ongoing study includes HPV-positive oropharyngeal can-
cer patients prior to surgery (NCT02002182). A current-
ly ongoing phase I/II trial is investigating the combination
of ADXS11-001 with durvalumab and comparing effica-
cy with durvalumab alone (NCT02291055). DPX-E7 is a
HPV16-E711-19 nanomer vaccine currently investigated
in HPV-positive cancers (NCT02865135)
TG4001 is based on the modified vaccinia virus Ankara
that carrys and expresses mutation-inactivated HPV16 E6
and E7 oncoproteins. A phase Ib/II study is investigating
this vaccine in combination with the anti-PD-L1 antibody
avelumab (NCT03260023).
Dendritic cell vaccines
HPV-targeting dendritic cell vaccines have been investi-
gated in cervical cancer. Although HPV-specific cytotoxic
T lymphocytes could be measured, no clinical responses
were observed [65, 66]. In preclinical models,the activity
of dendritic cell vaccines has been improved by using a
recombinant adenovirus expressing codon-optimised HPV
E6/E7 fusion proteins [67]. A dendritic cell-based vaccina-
tion against p53 was tested in a phase I trial in patients with
resected HNSCC [68]. Monocyte-derived dendritic cells
from 16 patients were loaded with two modified HLA-
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class I p53 peptides and were injected into inguinal lymph
nodes. The frequencies of p53-specific T cells were in-
creased in 11 of 16 patients (69%), with interferon-γ se-
cretion detected in 4 of 16 patients. Moreover, the rate of
Tregs was decreased after vaccination.
In conclusion, the currently most successful vaccination
strategy is preventive vaccination for HPV. Therapeutic
vaccines for HPV-associated HNSCC has been investi-
gated using different approaches. Although immune re-
sponses have been seen in most studies, these vaccines
are currently not effective enough for clinical use. Howev-
er, their combination with other immunotherapeutic strate-
gies, namely immune checkpoint inhibitors might be more
promising.
Cytokines
Interleukin-2 is one of the major proinflammatory cy-
tokines produced by T cells. It enhances the proliferation
and cytotoxic response of activated T cells [69]. Early tri-
als using interleukin-2 in HNSCC patients demonstrated
increased levels of cytokines, intratumoural levels of nat-
ural killer cells and activity of TILs [70, 71]. Perilymphatic
injection of interleukin-2 significantly prolonged disease-
free survival and overall survival of HNSCC patients and
was well tolerated [72]. However, an earlier trial investi-
gating combination therapy with interferon-α2a and inter-
leukin-2 showed substantial toxicity [73]. Although the re-
sponse rate of 18% was encouraging, this concept is no
longer pursued.
Furthermore, the use of interferon-γ demonstrated im-
munological and some level of clinical response [74]. In-
tratumoural injection of interleukin-12 led to increased in-
filtration of B cells into the tumour and higher levels of in-
terferon-γ. A shift in the plasma antibody profile towards a
Th1 phenotype and a redistribution of lymphocytes, mono-
cytes and natural killer cells from the peripheral blood to
lymph nodes was detected [75, 76]. IRX-2 is a cell-derived
mixture of cytokines including interleukins-1β, -2, -6 and
-8, interferon-γ, tumour necrosis factor-α, and granulocyte
and granulocyte-macrophage coloy stimulating factors (G-
CSF and GM-CSF). In preclinical models IRX-2 treat-
ment of human monocyte-derived dendritic cells resulted
in morphologic, phenotypic and functional changes con-
sistent with the development of mature activated dendritic
cells leading to increased ability to stimulate T cells and
increased interleukin-12 production [77, 78]. Furthermore,
IRX-2 reduced intratumoural levels of immunosuppres-
sive cytokines (interleukin-10, transforming growth factor-
β) while increasing levels of interferon-γ [78]. In an early
clinical trial, IRX-2 was injected peritumourally in 27 pa-
tients prior to surgery. During a 21-day neoadjuvant regi-
men, subcutaneous immunotherapy injections were admin-
istered over 10 days (Monday to Friday over a 2-week pe-
riod) as two bilateral injections of 115 U each in the mas-
toid region of the left and right neck in close proximity to
the regional nodal basins. The regimen also included a sin-
gle infusion of a non-cytotoxic dose of cyclophosphamide
(300 mg/m2) on day 1, and daily oral indomethacin (25 mg
three times daily) and zinc gluconate (24 mg once daily).
The neoadjuvant immunotherapy regimen was well toler-
ated with minimal toxicity [79]. Overall, 45.8% of patients
showed a decrease in tumour size. Overall survival was
92, 73 and 69% at 12, 24 and 36 months, respectively.
Compared with the initial biopsy, tumour resection spec-
imens showed an increased level of TILs. CD3+ CD4+
T cells and CD20+ B cells were primarily found in the
peritumoural stroma and CD3+ CD8+ T cells and CD68+
macrophages intratumourally. High frequencies of TILs
were associated with good clinical outcome. Therapy also
led to changes in the peripheral blood lymphocyte subsets,
with a decrease in B cells, natural killer cells and naïve
T cells [80]. The INSPIRE trial (NCT02609386) is a ran-
domised phase II trial investigating the neoadjuvant IRX-2
regimen in patients with stage II to IVA resectable squa-
mous cell carcinoma of the oral cavity and is currently re-
cruiting patients also at two sites in Switzerland.
In conclusion, cytokine immunotherapeutic strategies have
shown some encouraging results in HNSCC patients. Sys-
temic use is associated with substantial toxicity. However,
local injection into the tumour or the regional nodal basin
might be a promising alternative and is currently being in-
vestigated in ongoing studies. Targeted cytokine therapy
with chimeric constructs that show tumour specificity are
potentially less toxic, since lower doses of the cytokines
are needed. This approach is currently being tested in early
phase clinical trials.
Toll-like receptors
Toll-like receptors (TLRs) are a subclass of pattern-recog-
nition receptors that recognise pathogen-associated mole-
cules and have emerged as key mediators of immune func-
tions. TLRs are usually expressed on immune cells and
trigger local inflammation in response to binding partic-
ular molecules from pathogens (bacteria, viruses) such as
lipopolysaccharide and double-strand RNA. This mediates
protective function, but under certain circumstances this
may promote tumour progression by induction of cell pro-
liferation, activation of the NF-κB signalling pathway and
resistance to natural killer cells [81] (NF-κB = nuclear fac-
tor “kappa-light-chain-enhancer” of activated B-cells).
Agonists of TLRs have profound immune stimulatory ef-
fects in preclinical models. Motolimod (VTX-2337) is a
small molecule TLR-8 agonist that activates monocytes,
dendritic cells and natural killer cells [82]. In a phase Ib
study in patients with HNSCC, motolimod was combined
with cetuximab and demonstrated an overall response rate
of 17% and a disease control rate of 50% [83]. These data
and preclinical work showing synergistic activity of mo-
tolimod with platinum and fluorouracil led to the design
of a randomised phase II trial investigating the additional
benefit of motolimod together with the EXTREME regi-
men (NCT01836029).
The TLR-9 agonist EMD1201081 has been compared with
cetuximab in a randomised phase II trial involving recur-
rent/metastatic HNSCC patients after failure of one cyto-
toxic regimen [84]. There was no incremental clinical ef-
ficacy of the TLR-9 agonist. Another trial with the same
TLR-9 agonist in combination with cisplatin was stopped
early because of safety concerns (NCT01360827).
Cell-based therapies
Cell-based therapies include adoptive cell transfer and
chimeric antigen receptor (CAR) T cells. Adoptive cell
transfer involves the expansion of autologous antigen-spe-
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cific cytotoxic T lymphocytes ex vivo and the option to
genetically modify these cells prior to reinfusion. CAR
T cells are used to induce a stronger antitumour T cell
effect. This novel technique involves the use of naïve T
cells isolated from patients’ peripheral blood. CARs are
engineered membrane proteins composed of three parts:
an extracellular antigen-recognition region, a hinge and
transmembrane region, and an intracellular T cell activa-
tion domain [85]. The antigen-recognition part consists of
a single-chain variable fragment derived from hypervari-
able regions of an antibody’s immunoglobulin heavy and
light chains. This fragment has a higher affinity for tu-
mour-associated antigens than the classical T cell receptor.
This fragment is linked to the intracellular signalling re-
gion that is usually derived from the cytoplasmatic domain
of the CD3ζ chain. Furthermore, co-stimulatory molecules
are linked between the single-chain variable fragment and
the CD3ζ chain to improve T cell activation. In CAR ther-
apy, CARs are overexpressed in patient-derived T cells us-
ing a retroviral or lentiviral vector.
Adoptive cell transfer
In an initial study, E6 and E7 reactive cytotoxic T lym-
phocytes were used in nine patients with HPV-associated
cervical cancer, leading to complete remission in two of
them [86]. More recently, genetically modified cytotoxic
T lymphocytes expressing receptors against an HPV E6
and E7 epitope were shown to kill HPV-positive cells from
cervical and head and neck cancer cell lines [87]. This
model was tested in a phase I/II trial in 12 patients with
HPV-associated epithelial cancer (1 patient with oropha-
ryngeal carcinoma). E6-receptor T cell therapy was safe
and led to tumour regression in two patients with anal
cancer [88]. In another trial, patients with recurrent HN-
SCC received adoptive therapy with autologous peripheral
blood mononuclear leukocytes that had been opsonised
during culture with catumaxomab, an antibody that with
one arm binds epithelial cell adhesion molecule on tu-
mours and with the other arm binds CD3+ T cells [89].
This approach showed significant toxicity with a high cell
dose, but was well tolerated and led to clinical response
with lower numbers of CD3+ cells. In a combination of
active and adoptive immunisation, HNSCC patients were
vaccinated with irradiated autologous tumour plus GM-
CSF and then received adoptive transfer of their in vitro
expanded lymph node cells, including CD4+ and CD8+
cells [90]. This led to tumour response in 5 out of 17 pa-
tients with limited toxicity. In a trial in patients with surgi-
cally resected HNSCC, autologous tumour cells antigeni-
cally modified by infection with Newcastle disease virus
were used in combination with interleukin-2 and compared
with interleukin-2 treatment alone [91]. Vaccination plus
interleukin-2 increased levels of reactive T cells and pro-
longed overall survival.
CAR T cells
In HNSCC, CARs targeting latent membrane protein
(LMP)1-HELA/CAR in nasopharyngeal carcinoma [92] or
chondroitin sulphate proteoglycan-4 [93] induced an anti-
tumour effect in vitro and in vivo. In a preclinical model,
HER-2-specific CAR T cells were investigated after pre-
treatement with an oncolytic adenovirus that delivered a
construct encoding the PD-L1 blocking antibody and inter-
leukin-12p70 with a high response rate in a xenograft mod-
el [94]. There is currently an ongoing phase I trial investi-
gating an ErbB-specific CAR [95] (NCT01818323).
Immune checkpoint inhibitors
A broad range of immune checkpoint receptors have re-
cently been characterised and can be targeted by mono-
clonal antibodies [96]. So far, mainly antibodies targeting
inhibitory checkpoint receptors have been investigated in
clinical trials. These drugs re-activate the antitumoural im-
mune response and have recently shown impressive results
in different solid tumours, such as melanoma, non-small
cell lung cancer, and renal cell carcinoma [97–99]. Unlike
conventional tumour cell-directed antibodies or
chemotherapeutic agents, immune checkpoint inhibitors do
not target cancer cells directly, but bind receptors or their
ligands on immune cells and therefore modulate their ac-
tivity. Interestingly, these drugs might induce long-lasting
remissions in advanced and metastatic solid tumours even
after discontinuation of therapy [100].
The role of CTLA-4 inhibitors is not yet established in
HNSCC. However, in a recent study it was demonstrated
that cetuximab increased CTLA-4 expression in the ma-
jority of intratumoural Tregs and it was also shown that
the CTLA-4 inhibitor ipilimumab decreased suppression
of natural killer cells from Tregs [101]. Ipilimumab and
another CTLA-4-targeting monoclonal antibody, tremeli-
mumab, are currently being investigated in combination
with cetuximab and radiotherapy in patients with advanced
HNSCC.
Metastatic disease
Nivolumab and pembrolizumab are anti-PD-1 antibodies.
So far, the only fully published randomised phase III trial
(CheckMate 141) compared nivolumab with standard of
care therapy in patients with recurrent/metastatic HNSCC
refractory to platinum therapy [102]. A total of 361 pa-
tients with disease progression or recurrence within 6
months after the last dose of platinum-based chemotherapy
– either in the curative setting combined with radiotherapy
or the palliative setting as part of multiagent chemotherapy
– were randomised in a 2:1 manner between nivolumab 3
mg/kg every 2 weeks and single agent chemotherapy at the
investigator’s discretion (methotrexate, docetaxel or cetux-
imab). After an interim analysis, the trial was stopped ear-
ly and patients in the chemotherapy arm were allowed to
cross over to nivolumab, on the recommendation of the
independent data monitoring committee. More than half
of the patients had two or more previous therapy lines.
At the final analysis, nivolumab significantly prolonged
overall survival (7.5 vs 5.1 months; hazard ratio 0.70, p
= 0.0101), whereas progression-free survival was not dif-
ferent. Survival rates after one year were more than dou-
bled with nivolumab (16.6 vs 36%). Survival benefit was
independent of HPV status but seemed to be stronger in
p16 positive patients. The effect of nivolumab on overall
survival was more pronounced in PD-L1 positive patients.
The study included extensive quality of life analysis and
patient-reported outcomes [103]. Nivolumab stabilised
symptoms, whereas investigator’s choice therapy led to
clinically meaningful deterioration. Furthermore, nivolum-
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ab delayed time to deterioration of patient-reported out-
comes compared with chemotherapy.
Pembrolizumab was approved for HNSCC in the US on
the basis of the Keynote-012 study [104]. In this phase Ib
study, 60 patients with recurrent/metastatic HNSCC, irre-
spective of previous therapy, with a PD-L1 expression of at
least 1% of tumour cells were treated with pembrolizumab
10 mg/kg every two weeks. The majority of patients were
heavily pretreated with two or more previous treatment
lines. Half of the patients experienced reduction of tumour
burden with an overall response rate based on Response
Evaluation Criteria In Solid Tumours (RECIST) criteria of
18%. Median duration of response was 53 weeks. progres-
sion-free and overall survival were 2 and 13 months, re-
spectively. PD-L1 positivity was assessed using two dif-
ferent methods: (1) the combined positive score, defined
as ≥1% of expression in both tumour and mononuclear in-
flammatory cells and (2) the tumour proportion score de-
fined as ≥1% of expression only in tumour cells. The study
showed a relation between PD-L1 positivity and efficacy
only with the combined positive score. HPV status deter-
mined by p16 immunohistochemistry was not predictive
for response to pembrolizumab. The authors reported on
six interferon-γ-related genes associated with tumour re-
sponse. In an expansion cohort of Keynote-012, the results
were confirmed in a total of 132 patients with an overall
response rate of 18%, and progression-free and overall sur-
vival of 2 and 8 months, respectively [105]. In a recently
presented analysis of the Keynote-012 study, patients with
a T cell inflamed gene expression profiling showed a high-
er response rate irrespective of their HPV status [106]. A
recent study analysed the gene expression profile in the
tumour microenvironment, using RNA from different sol-
id tumours treated with pembrolizumab [107]. An 18-gene
T cell inflamed gene expression profile was predictive of
response to pembrolizumab independently of PD-L1 ex-
pression. In a follow-up phase II trial (Keynote-055), 171
patients refractory to platinum and cetuximab (disease pro-
gression within 6 months of therapy) were treated with
pembrolizumab 200 mg every 3 weeks [108]. Seventy-five
percent of patients received two or more prior lines of
therapy for metastatic disease. Overall response rate was
16%, with a median duration of response of 8 months;
75% of responses were ongoing at the time of analysis.
Response rates were similar in all HPV and PD-L1 sub-
groups. Median progression-free survival was 2.1 months,
and median overall survival was 8 months. Keynote-040
was a randomised phase 3 trial investigating pembrolizum-
ab in patients with recurrent/metastatic HNSCC after plat-
inum-based first-line chemotherapy [109]. A total of 495
patients were randomised in a 1:1 manner to either pem-
brolizumab 200 mg every 3 weeks or treatment of the
investigator’s choice (methotrexate, docetaxel, or cetux-
imab). Pembrolizumab prolonged overall survival, but the
difference did not achieve significance (8.4 vs 7.1 months;
hazard ratio 0.81; 95% confidence interval 0.66–0.99; p =
0.0204). There was no difference in progression-free sur-
vival. Among patients with a PD-L1 combined positive
score of at least 1%, median overall survival was 8.7
months with pembrolizumab versus 7.1 months with stan-
dard therapy (hazard ratio 0.75; p = 0.0078), and among
patients with combined positive score expression in more
than 50% of their cancer cells, median overall survival was
11.6 versus 7.9 months, respectively (hazard ratio 0.54; p
= 0.0017).
Durvalumab is a monoclonal antibody against PD-L1. In
the 1108 study, 62 patients with recurrent/metastatic HN-
SCC and with at least one prior therapy received dur-
valumab monotherapy [110]. Overall response rate was
11.3%, with six of seven patients showing a response du-
ration of more than 1 year. The one-year survival rate was
reported to be 42%.
Based on these results, PD-1 inhibitors can be considered
a new standard of care in the second-line treatment of pa-
tients with recurrent/metastatic HNSCC. Published results
for this setting are summarised in table 1. Randomised tri-
als are currently investigating the role of these drugs in
the first-line setting. KEYNOTE-048 (NCT02358031) is a
randomised study with three arms. In the standard treat-
ment arm patients receive chemotherapy (platinum and
5-fluorouracil) in combination with cetuximab based on
the EXTREME protocol [7]. In the two experimental arms
patients either receive pembrolizumab in combination with
platinum plus 5-fluorouracil or pembrolizumab alone.
Pembrolizumab is given at a dose of 200 mg every 3
weeks for up to 24 months. The primary endpoint of the
study is progression-free and overall survival. The study
enrolled 825 patients and recruitment is currently closed.
So far, no results have been presented. CheckMate 651
(NCT02741570) is another randomised trial investigating
the combination of nivolumab and ipilimumab compared
to standard chemotherapy (platinum + 5-fluorouracil)
combined with cetuximab. The study is currently recruit-
ing, with a target enrollment of 700 patients. Primary end-
point of the trial is overall and progression-free survival.
In the Kestrel study (NCT02551159), with a similar de-
sign, more than 800 patients will be randomised to either
the EXTREME regimen, durvalumab monotherapy, or dur-
valumab in combination with the anti-CTLA-4 antibody
tremelimumab. Table 2 provides an overview on ongoing
randomised phase III trials.
Combination therapies including different immune check-
point inhibitors have recently been shown to improve re-
sponse rates and prognosis compared with PD-1/PD-L1
Table 1: Immune checkpoint inhibitors for recurrent/metastatic head and neck squamous cell carcinoma.
Study Phase Drug No. patients ORR (%) Median PFS (months) Median OS (months)
CheckMate 141 [102] III Nivolumab
SOC
240
121
13.3%
5.8%
2.0
2.3
7.5
5.1
Keynote-012 [104] Ib Pembrolizumab 60 18% 2 13
Keynote-012 [105] Ib expansion Pembrolizumab 132 18% 2 8
Keynote-055 [108] II Pembrolizumab 171 16% 2.1 8
Keynote-040 [109] III Pembrolizumab
SOC
247
248
14.6%
10.1%
2.1
2.3
8.4
7.1
1108 [110] Ib Durvalumab 62 11.3% NR 42% after 1 year
ORR = overall response rate; OS = overall survival; PFS = progression-free survival; SOC = standard of care (methotrexate, docetaxel or cetuximab)
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monotherapy in patients with various solid tumours. Re-
cently, first clinical study data for immune checkpoint
combinations have been presented for patients with HN-
SCC. Epacadostat is an oral inhibitor of in-
doleamine-2,3-dioxygenase 1, an intracellular enzyme that
initiates the first and rate-limiting step of tryptophan degra-
dation in the kynurenine pathway [111]. Indoleamine-
dioxygenase supports inflammation in the tumour mi-
croenvironment, development of immune tolerance in stro-
mal and immune cells, suppression of T and natural killer
cells, generation and activation of Tregs and myeloid-de-
rived suppressor cells, and promotion of tumour angio-
genesis [112]. In a recently presented phase II trial
(ECHO-202/Keynote-037), 38 patients with recurrent/
metastatic HNSCC after failure of at least one prior
chemotherapy regimen including a platinum agent were
treated with epacadostat 100 mg daily and pembrolizumab
200 mg every 3 weeks [113]. The combination therapy led
to a disease response in 34% of patients and a disease con-
trol rate of 39% with most of the responses ongoing at
the time point of analysis. Responses were seen indepen-
dently from HPV and PD-L1 status. Toxicities of grade 3
or 4 were seen in 18% of patients, including one patient
with pneumonitis. One patient died as a result of aspira-
tion pneumonia. However, pneumonitis could not be ruled
out. PD-1/PD-L1 and CTLA-4 inhibition showed synergis-
tic activity in various tumours [114, 115].
Monalizumab (previously IPH2201) is a IgG4 antibody
targeting NKG2A, an inhibitory receptor expressed on tu-
mour infiltrating cytotoxic natural killer and CD8 T lym-
phocytes. In a phase Ib/II study, monalizumab was tested
in combination with cetuximab in recurrent/metastatic
HNSCC. In a preliminary report of the phase Ib part of the
trial, combination therapy showed a good safety profile in
17 patients [116].
Localised and locally advanced disease
The current standard of care for patients with locally ad-
vanced HNSCC is tumour resection followed by radiother-
apy or platinum-based chemoradiotherapy (CRT). Organ
preservation by means of definitive radiotherapy in combi-
nation with platinum chemotherapy or cetuximab is a well-
established alternative. Recently, a study investigating the
combination of pembrolizumab with definitive CRT was
presented [117]. In this trial, 27 patients with stage III-IVB
HNSCC of the oro- or hypopharynx, or larynx, irrespec-
tive of HPV status, were treated with pembrolizumab at
a fixed dose of 200 mg 4 to 7 days prior to initiation of
CRT and then every 3 weeks during CRT (two concomi-
tant doses) and then after CRT for five additional doses.
CRT consisted of six doses weekly cisplatin 40 mg/m2 giv-
en concurrently with radiation at a dose of 2 Gy once daily
for 35 fractions (cumulative dose 70 Gy). At the time of
the presented interim analysis, 21 patients (78%) had re-
ceived all planned doses of pembrolizumab. Three patients
discontinued therapy because of immune-related adverse
events and three patients for protocol reasons. All patients
completed the full dose of radiotherapy without significant
delays (defined as >5 days). Twenty-three patients (85%)
received the goal target dose of cisplatin (≥200 mg/m2).
At day 150 after the initiation of CRT, 21 patients (78%)
had a complete response, 4 patients had a partial response
and 1 patient developed disease progression. The study
(NCT02586207) is currently recruiting patients and further
efficacy analyses are expected. Another trial included pa-
tients with stage III or IV HPV-negative HNSCC. Patients
were treated with one dose of pembrolizumab 200 mg prior
to tumour resection [118]. Patients with high-risk patho-
logical features (positive resection margin and/or extra-
capsular extension in lymph node metastasis) were given
postoperative cisplatin and radiotherapy followed by pem-
brolizumab. At the time of the first report of this study, 21
patients were enrolled. Importantly, this study did not show
any serious study-drug related adverse event, unexpected
surgical delay, or postoperative complications. None of the
14 patients with a follow-up of at least 1 year experienced
loco-regional recurrence or disease specific death. Forty-
two percent of patients experienced a pathological treat-
ment response to neoadjuvant pembrolizumab, defined as
tumour necrosis and/or a giant cell or histiocytic reaction
to keratinous debris in >10% of the tumour area. The au-
thors reported a significant correlation between baseline
PD-L1 expression on tumour cells and pathological treat-
ment effect in the tumour. Currently, several ongoing clini-
cal studies are investigating immune checkpoint inhibitosr
in the setting of locally advanced HNSCC. In Switzerland,
JAVELIN Head and Neck 100 (NCT02952586) is current-
ly recruiting patients. This phase III randomised, placebo-
controlled study evaluates the safety and antitumour activ-
ity of the anti-PD-L1 antibody avelumab in combination
with standard of care CRT versus CRT alone.
Other immune checkpoint proteins that can be expressed
on T cells include BTLA (B- and T-lymphocyte attenua-
tor), LAG3 and TIM3. Antibodies that block the binding
of these proteins to their ligands are being developed and
tested in clinical trials.
Table 2: Ongoing phase III trials with immune checkpoint inhibitors.
Study NCT number Setting Treatment No. patients
CheckMate 651 NCT02741570 1st-line Nivolumab + ipilimumab vs
EXTREME regimen
700
KEYNOTE-048 NCT02358031 1st-line Pembrolizumab vs
EXTREME regimen + pembrolizumab vs
EXTREME regimen
825
Kestrel NCT02551159 1st-line Durvalumab vs
durvalumab + tremelimumab vs
EXTREME regimen
823
Eagle NCT02369874 2nd-line Durvalumab vs
durvalumab + tremelimumab vs
SOC
736
EXTREME regimen = cisplatin + 5-fluorouracil + cetuximab; SOC = standard of care (methotrexate, docetaxel or cetuximab)
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Immune checkpoint activators
Compared with the inhibitory checkpoint receptor anti-
bodies, an immunostimulatory effect is induced through
the activation of member of the tumour necrosis factor-
receptor superfamily on T cells [119]. The stimulatory
checkpoint receptors and their ligands most investigated
so far are OX40 (OX40-ligand), CD137 (4-1BB ligand),
and CD27 (CD70). OX40 is expressed on activated T cell.
Stimulation of OX40 by activating antibodies suppresses
T cell apoptosis and induces production of immunostimu-
latory cytokines. An ongoing clinical trial is investigating
the OX40 agonist MEDI6469 in a neoadjuvant setting in
HNSCC patients (NCT02274155). Other OX40 agonists
(MEDI0562, PF-04518600) are currently in phase I trials
in different solid tumours. Urelumab is an agonistic anti-
body towards CD137 that is expressed on the surface of
different immune cells including natural killer cells. In a
phase I study urelumab is being investigated in combina-
tion with cetuximab in patients with HNSCC and colorec-
tal carcinoma (NCT02110082). The study has terminated
accrual but no results have been reported so far. In a pre-
clinical study, it was shown that urelumab enhanced ce-
tuximab-activated natural killer cell survival, dendritic cell
maturation and tumour antigen cross-presentation [120].
Varlilumab is a CD27 agonist and is currently being inves-
tigated in combination with nivolumab (NCT02335918),
as well as with atezolizumab (NCT02543645). The
JAVELIN Medley trial (NCT02554812) is a phase Ib/II
trial investigating the inhibitory antibody against PD-L1
avelumab in combination with different other cancer im-
munotherapies including PF-04518600 and the anti-4-1BB
antibody utomilumab.
Conclusions
Introduction of novel technologies to assess the tumour mi-
croenvironment has led to a profound understanding of im-
munosuppressive mechanisms in HNSCC tissue. Immune
checkpoint inhibitors targeting the PD-1/PD-L1 axis repre-
sent a new standard of care for platinum-refractory recur-
rent/metastatic HNSCC patients. Ongoing clinical studies
are investigating their role in the first-line palliative as well
as in the curative setting. For future development it will
be crucial to identify markers predictive of immunotherapy
response to better characterise patients who will eventually
benefit from these drugs.
Prophylactic HPV vaccination showed significant reduc-
tion of oral HPV infections and seems to be an effective
strategy in the prevention of HPV-related HNSCC, which
has recently shown rising incidence. Therapeutic vaccina-
tion and cell-based therapies have shown interesting re-
sponse rates in early clinical trials and are currently being
further investigated in different settings in HNSCC pa-
tients. Combination of different immunotherapeutic ap-
proaches could affect different phases of immune response,
eventually leading to an improved response and outcome
compared with monotherapy. Rational treatment combina-
tion strategies are currently under investigation and might
further improve the outcome of HNSCC patients.
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